Title:
PYRIMIDINE DERIVATIVES
Document Type and Number:
WIPO Patent Application WO/2022/199589
Kind Code:
A1
Abstract:
A series of pyrimidine derivatives and the use thereof in the preparation of a drug for treating related diseases. Specifically disclosed are a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug for treating related diseases
More Like This:
| WO/1998/027108 | NEW AMIDE COMPOUNDS AND THEIR USE AS NITRIC OXIDE SYNTHASE INHIBITORS |
| JPH05339263 | DIHYDROPYRIDINE DERIVATIVE |
| WO/2021/170070 | USES OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR |
Inventors:
WU LINGYUN (CN)
WANG CAILIN (CN)
ZHAO LELE (CN)
LI JIAN (CN)
CHEN SHUHUI (CN)
WANG CAILIN (CN)
ZHAO LELE (CN)
LI JIAN (CN)
CHEN SHUHUI (CN)
Application Number:
PCT/CN2022/082343
Publication Date:
September 29, 2022
Filing Date:
March 22, 2022
Export Citation:
Assignee:
MEDSHINE DISCOVERY INC (CN)
International Classes:
C07D401/12; A61K31/505; A61K31/66; A61P1/16; A61P25/00; A61P31/06; A61P31/12; A61P35/00; C07D239/48; C07D401/04; C07D471/10; C07D487/00; C07F9/6558
Domestic Patent References:
| WO2019120121A1 | 2019-06-27 | |||
| WO2012151561A1 | 2012-11-08 | |||
| WO2020200191A1 | 2020-10-08 | |||
| WO2020249048A1 | 2020-12-17 | |||
| WO2017086829A1 | 2017-05-26 | |||
| WO2021125803A1 | 2021-06-24 | |||
| WO2021190417A1 | 2021-09-30 | |||
| WO2018102366A1 | 2018-06-07 |
Foreign References:
| CN110467637A | 2019-11-19 | |||
| CN110467638A | 2019-11-19 | |||
| CN111718325A | 2020-09-29 | |||
| CN102105150A | 2011-06-22 | |||
| CN103153064A | 2013-06-12 | |||
| US20140066406A1 | 2014-03-06 | |||
| CN106699810A | 2017-05-24 | |||
| CN109071512A | 2018-12-21 |
Other References:
CHEN, YONGFEI ET AL.: "Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1, 4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 139, 31 December 2017 (2017-12-31), pages 674 - 697, XP055600563, DOI: 10.1016/j.ejmech.2017.08.035
HUANG, WEISHENG ET AL.: "Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 10, 31 December 2016 (2016-12-31), pages 4948 - 4964, XP055480025, DOI: 10.1021/acs.jmedchem.6b00306
HUANG, WEISHENG ET AL.: "Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 10, 31 December 2016 (2016-12-31), pages 4948 - 4964, XP055480025, DOI: 10.1021/acs.jmedchem.6b00306
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF:
Previous Patent: SEAMLESS COMBINATION FROG
Next Patent: NANOBODY TARGETING BCMA AND APPLICATION THEREOF
Next Patent: NANOBODY TARGETING BCMA AND APPLICATION THEREOF